期刊文献+

磷酸西格列汀在2型糖尿病治疗中的应用研究 被引量:3

Efficacy of Sitagliptin Phosphate in Treatment of Type Ⅱ Diabetes
下载PDF
导出
摘要 目的对磷酸西格列汀应用于2型糖尿病治疗中的效果进行分析研究。方法选取于2013年11月-2015年12月在我院收治的2型糖尿病患者116例,并随机分为对照组和治疗组各58例,观察并比较常规治疗和加用磷酸西格列汀的效果。结果治疗组患者的治疗总有效率高于对照组[93.1%vs 75.9%],治疗组患者的空腹血糖、餐后2 h血糖、糖化血红蛋白以及胰高血糖素水平均低于对照组,组间差异经t检验,有统计学意义(P〈0.05)。结论磷酸西格列汀应用于2型糖尿病治疗中的效果确切。 Objective Sitagliptin Phosphate effect in treatment of type II diabetes is to be analyzed. Methods chose 116 patients of type II diabetes who were treated in hospital from November 2013 to December 2015 and separated them into Control Group and Study Group randomly with 58 patients in each group, and then observed and compared conventional medication effect to Sitagliptin Phosphate treatment effect. Results The treatment efficacy in Study Group was also higher than that in Control Group [93.1% vs 75.9%]; while, patients' fasting blood glucose, postprandial 2 hours' blood glucose, glycosylated hemoglobin and glucagon level in Study Group were significantly lower than counterparts in Control Group; there was a difference between groups according to T-Check, and such a differential had statistic vale(P〈0.05). Conclusion Sitagliptin Phosphate application is effective in treatment of type II diabetes, thus, such a medication treatment is quite worthwhile to be promoted widespread.
作者 李金玲
出处 《中国卫生标准管理》 2016年第1期85-86,共2页 China Health Standard Management
关键词 磷酸西格列汀 2型糖尿病 Sitagliptin phosphate Type II diabetes
  • 相关文献

参考文献5

二级参考文献49

  • 1Fiona TH Lee. Advances in diabetes therapy in the elderly[J]. J Pharrn Pract Res, 2009, 39(1): 63-67.
  • 2Barzilai N, Guo H, Mahoney EM, et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial[J]. Curr Med Res Opin, 2011, 27(5): 1049-1058.
  • 3Mohan V, Yang W, Son HY, et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea[J]. Diabetes Res Clin Pract, 2009, 83(1): 106-116.
  • 4Amori R, Lau J, Pitt,as A. Efficacy and safety of incretin therapy in type 2 diabetes[J]. JAMA, 2007, 298: 194-206.
  • 5Mu J, Woods J, Zhou YP, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic {beta}- cell mass and function in a rodent model of type 2 diabetes[J]. Diabetes, 2006, 55(6): 1695-1704.
  • 6Scheen AJ. Pharmacokinetics of dipeptidyl peptidase-4 inhibitors[J]. Diabetes Obes Metab, 2010, 12(8): 648-658.
  • 7Xu L, Man CD, Charbonnel B, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell fimction in patients with type 2 diabetes: a model-based approach[J]. Diabetes Obes Metab, 2008, 10(12): 1212-1220.
  • 8Schwartz SL. Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors[J]. Am J Geriatr Pharmacother, 2010, 8(5): 405-418.
  • 9Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis[J]. Diabetes Care, 2010, 33(11): 2349-2354.
  • 10中华医学会糖尿病学分会.中国2 型糖尿病防治指南(2010 年版)[M].北京:北京大学医学出版社,2011:13.

共引文献53

同被引文献28

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部